Versions

 

PIB 4.13.3 Guidance

1. The use of techniques to reduce or transfer Credit Risk may simultaneously increase other risks (residual risks) which include legal, operational, liquidity and Market Risks. The DFSA expects an Authorised Firm to employ methods to identify and control these risks, including:
a. strategy;
b. consideration of the underlying credit;
c. valuation;
d. policies and procedures;
e. systems;
f. control of roll-off risks; and
g. management of Concentration Risk arising from the use of Credit Risk mitigation and the interaction of such risk with the overall Credit Risk profile of the Authorised Firm.
2. In order to fulfil the above, an Authorised Firm should ensure a clearly articulated strategy for the use of Credit Risk mitigation as an intrinsic part of the general credit strategy of an Authorised Firm.
3. Where an Exposure is subject to Credit Risk mitigation, credit managers should continue to assess the Exposure on the basis of the obligor's creditworthiness. Credit managers should obtain and analyse sufficient financial information to determine the obligor's risk profile and its management and operational capabilities.
4. Collateral should be revalued frequently, and the unsecured Exposure should also be monitored frequently. Frequent revaluation is prudent, and the revaluation of marketable securities should occur on at least a daily basis. Furthermore, measures of the potential unsecured Exposure under collateralised transactions should be calculated under stressed and normal conditions. One such measure would take account of the time and cost involved if the obligor or Counterparty were to default and the Collateral had to be liquidated. Furthermore, the setting of limits for collateralised Counterparties should take account of the potential unsecured Exposure. Stress tests and scenario analysis should be conducted to enable the Authorised Firm to understand the behaviour of its portfolio of Credit Risk mitigation arrangements under unusual market conditions. Any unusual or disproportionate risk identified should be managed and controlled.
5. Clear policies and procedures should be established in respect of Collateral management, including:
a. the terms of Collateral agreements;
b. the types of Collateral and enforcement of Collateral terms (e.g. waivers of posting deadlines);
c. the management of legal risks;
d. the administration of agreement (e.g. detailed plans for determining default and liquidating Collateral); and
e. the prompt resolution of disputes, such as valuation of Collateral or positions, acceptability of Collateral, fulfilment of legal obligations and the interpretation of contract terms.
6. The policies and procedures referred to under Guidance note 1(d) should be supported by Collateral management systems capable of tracking the location and status of posted Collateral (including re-hypothecated Collateral), outstanding Collateral calls and settlement problems.
7. Where an Authorised Firm obtains credit protection that differs in maturity from the underlying credit Exposure, the Authorised Firm should monitor and control its roll-off risks, i.e. the fact that the Authorised Firm will be fully exposed when the protection expires, and the risk that it will be unable to purchase credit protection or ensure its capital adequacy when the credit protection expires.
8. Taking as Collateral large quantities of instruments issued by one obligor creates Concentration Risk. An Authorised Firm should have a clearly defined policy with respect to the amount of Concentration Risk it is prepared to run. Such a policy might, for example, include a cap on the amount of Collateral it would be prepared to take from a particular Issuer or market. The Authorised Firm should also take Collateral and purchased credit protection into account when assessing the potential concentrations in its overall credit profile.
9. Notwithstanding the presence of Credit Risk mitigation considered for the purposes of calculating Credit RWA amounts, an Authorised Firm should continue to undertake a full Credit Risk assessment of the underlying Exposure.
Derived from RM111/2012 (Made 15th October 2012). [VER20/12-12]